학술논문
Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes
Document Type
article
Author
Source
Revista da Associação Médica Brasileira. September 2020 66(9)
Subject
Language
English
ISSN
0104-4230
Abstract
SUMMARY The pharmacological therapy for type 2 diabetes mellitus has presented important advances in recent years, which has impacted the treatment of patients with established cardiovascular disease or with high cardiovascular risk. In this scenario, two drug classes have emerged and demonstrated clear clinical benefits: SGLT-2 inhibitors and GLP-1 agonists. The present review discusses the pharmacology, adverse effects, and clinical trials that have demonstrated the benefits of these medications in reducing cardiovascular risk.